Low vitamin K status, high sclerostin and mortality risk of stable coronary heart disease patients

• Published in: Biomarkers in medicine 2021-11, Vol.15 (16), p.1465-1477
• Main Authors: Mayer, Otto, Bruthans, Jan, Seidlerová, Jitka, Gelžinský, Julius, Kučera, Radek, Karnosová, Petra, Mateřánková, Markéta, Rychecká, Martina, Wohlfahrt, Peter, Cífková, Renata, Filipovský, Jan, Vermeer, Cees
• Format: Article
• Language: English
• Subjects: all-cause death; cardiovascular death; dp-ucMGP; EUROASPIRE; heart failure; matrix γ-carboxyglutamate protein (MGP); nonfatal cardiovascular events; Wnt/β-catenin pathway
• ISSN: 1752-0363; 1752-0371
• DOI: 10.2217/bmm-2021-0168

We explored whether matrix Gla protein (MGP, natural calcification inhibitor) and sclerostin (glycoprotein responsible for osteoblast differentiation) interact in terms of mortality risk in coronary patients. 945 patients after myocardial infarction and/or coronary revascularization were followed in a prospective study. All-cause death, fatal or nonfatal cardiovascular events and heart failure hospitalizations were registered. Either high desphospho-uncarboxylated MGP (dp-ucMGP) or high sclerostin were independently associated with 5-year all-cause/cardiovascular mortality. However, we observed an additional mortality risk in the coincidence of both factors. Concomitantly high dp-ucMGP (≥884 pmol/l) plus sclerostin (≥589 ng/l) were associated with increased all-cause mortality risk compared with ‘normal’ concentration of both factors (HRR 3.71 [95% CI: 2.07–6.62, p